Edgewise Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
133
- Stock Symbol
-
EWTX
- Share Price
-
$41.17
- (As of Thursday Closing)
Edgewise Therapeutics General Information
Description
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Contact Information
Website
www.edgewisetx.comCorporate Office
- 1715 38th Street
- Boulder, CO 80301
- United States
Corporate Office
- 1715 38th Street
- Boulder, CO 80301
- United States
Edgewise Therapeutics Stock Performance
As of 19-Nov-2026, Edgewise Therapeutics’s stock price is $41.17. Its current market cap is $4.51B with 109M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $41.17 | $41.37 | $19.76 - $48.78 | $4.51B | 109M | 1.53M | $9.35 |
Edgewise Therapeutics Financials Summary
As of 30-Sep-2026, Edgewise Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,952,209 | 2,067,966 | 2,040,087 | 410,103 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | 1,135,303 | (189,140) | (156,542) | (112,625) |
| Net Income | 1,009,595 | (167,795) | (133,813) | (100,163) |
| Total Assets | 1,780,020 | 552,603 | 486,817 | 340,035 |
| Total Debt | 3,383 | 3,990 | 4,737 | 5,414 |
Edgewise Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Edgewise Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Edgewise Therapeutics Comparisons
Industry
Financing
Details
Edgewise Therapeutics Competitors (8)
One of Edgewise Therapeutics’s 8 competitors is Dyne Therapeutics, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dyne Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Solid Biosciences | Formerly VC-backed | Charlestown, MA | ||||
| Cytokinetics | Formerly VC-backed | South San Francisco, CA | ||||
| Epirium Bio | Venture Capital-Backed | San Diego, CA |
Edgewise Therapeutics Patents
Edgewise Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026102326-A1 | Pyridazinone compositions and methods for the treatment of muscular conditions | Pending | 08-Nov-2024 | ||
| WO-2026076029-A1 | Thiadiazine compounds and uses thereof | Pending | 02-Oct-2024 | ||
| WO-2025217000-A1 | 1,4-dihydroquinazolinone compositions for the treatment of cardiac conditions | Pending | 12-Apr-2024 | ||
| WO-2025207679-A1 | Quinazoline dione compounds and uses thereof | Pending | 26-Mar-2024 | ||
| WO-2025207677-A1 | Quinazolinone compounds and uses thereof | Pending | 26-Mar-2024 | C07D471/04 |
Edgewise Therapeutics Signals
Edgewise Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Edgewise Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.63 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Edgewise Therapeutics FAQs
-
When was Edgewise Therapeutics founded?
Edgewise Therapeutics was founded in 2017.
-
Where is Edgewise Therapeutics headquartered?
Edgewise Therapeutics is headquartered in Boulder, CO.
-
What is the size of Edgewise Therapeutics?
Edgewise Therapeutics has 133 total employees.
-
What industry is Edgewise Therapeutics in?
Edgewise Therapeutics’s primary industry is Drug Discovery.
-
Is Edgewise Therapeutics a private or public company?
Edgewise Therapeutics is a Public company.
-
What is Edgewise Therapeutics’s stock symbol?
The ticker symbol for Edgewise Therapeutics is EWTX.
-
What is the current stock price of Edgewise Therapeutics?
As of 19-Nov-2026 the stock price of Edgewise Therapeutics is $41.17.
-
What is the current market cap of Edgewise Therapeutics?
The current market capitalization of Edgewise Therapeutics is $4.51B.
-
Who are Edgewise Therapeutics’s competitors?
Dyne Therapeutics, Sarepta Therapeutics, Solid Biosciences, Cytokinetics, and Epirium Bio are some of the 8 competitors of Edgewise Therapeutics.
-
What is Edgewise Therapeutics’s annual earnings per share (EPS)?
Edgewise Therapeutics’s EPS for 12 months was $9.35.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process